Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KWQWKWQWK-Ahx-KKWQWK
- Development stage
- Preclinical
- Lead developer
- Universidad Nacional de Colombia
- Modality
- Peptides
01
Overview
KWQWKWQWK-Ahx-KKWQWK is a synthetic hybrid cationic peptide developed as a potential therapeutic for cervical cancer. It consists of a modified palindromic core sequence (KWQWKWQWK) derived from bovine lactoferricin (LfcinB) and a modified anticancer peptide fragment (KKWQWK), joined by a 6-aminohexanoic acid (Ahx) spacer. In this specific variant, all Arginine residues from the parent sequences (RWQWRWQWR and RRWQWR) have been substituted with Lysine to evaluate the impact on synthesis cost and biological activity. The peptide demonstrates rapid, concentration-dependent cytotoxicity against HeLa and Ca Ski cervical cancer cell lines, primarily through electrostatic interaction with negatively charged cell surface components followed by membrane disruption or internalization to induce apoptosis.
Beyond the preview
Go deeper on KWQWKWQWK-Ahx-KKWQWK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KWQWKWQWK-Ahx-KKWQWK.